
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Leading EDC Company Adds Offerings to Further Drive Efficiencies Across the Clinical Research Process.






